Founded in 2003 by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic, Synairgen plc is a UK-based drug discovery and biotechnology company engaged in developing drugs for respiratory diseases and Covid-19. Its primary drug is SNG001, inhaled interferon beta that is being researched as a treatment for Covid-19. Its shares are traded on the Alternative investment market segment of the London Stock Exchange as LON: SNG.
The company’s BioBank platform comprises of blood, bronchial epithelial cells, nasal lavage, sputum, biopsies and fibroblasts, which is used to develop a number of advanced tissue models for successful drug development. Its two models include InVitro models and Ex Vivo models, which are used to progress opportunities into clinical development. These models are used to discover novel drug targets; to identify disease related lesions and underlying molecular mechanisms; for testing and validation; for conducting screening assays and to support clinical trials. The company aims to realize values via licensing transactions. It entered into a partnership with Pharmaxis in 2015 to develop an oral LOXL2 inhibitor that can reduce fibrosis with idiopathic pulmonary fibrosis (IPF), the agreement was amended and pharmaxis took full responsibility in 2017.
The company’s drug program includes IFN-Beta, IFN-Beta (SNG001) in Asthma, IFN-Beta in COPD and LOXL2 inhibitors in Fibrotic disease. The IFN-Beta is a naturally-occurring protein that protects cells from infection and viruses such as MERS-CoV, SARS-CoV and SARS-CoV-2, which causes covid-19. The company is developing a formulation of IFN-beta, called SNG001, which can be used for the treatment of the covid-19. Its two trials shown improving lung function in patients with a cold or flu infection. In 2020, the company signed an agreement with Clinigen group to launch a managed access program the company’s IFN-beta, SNG001for treating Covid patients in the EU and UK.
The IFN-Beta (SNG001) in Asthma is used to treat or prevent asthma exacerbation caused by common cold and the result showed that the antiviral responses were improved and could reduce the spread of virus to the lungs by adding a small amount of INF-beta to cultures of lung cells.
The IFN-Beta (SNG001) in COPD is a naturally occurring protein that that is used to treat Chronic Obstructive Pulmonary Disease (COPD), which is majorly caused by long-term cigarette smoking by orchestrating the body’s anti-viral defenses.
LOXL2 is an enzyme released from fibroblasts that link collagen fibers together to stiffen scar tissue and excessive production and linking of collagen fibers results in fibrosis. It is used to treat Fibrotic disease.
Southampton General Hosp, Tremona Road SO16 6YD United Kingdom